Automated System for Monitoring Urine Output in Intensive Care Patients
Launched by MEIR MEDICAL CENTER · Feb 1, 2022
Trial Information
Current as of July 12, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how using an automated system to monitor urine output can help prevent acute kidney injury (a serious condition where the kidneys suddenly stop working well) in patients in the Intensive Care Unit (ICU). When patients are admitted to the ICU, keeping a close eye on how much urine they are producing is very important because it can help doctors detect problems early and improve patient care. The trial will compare two groups of patients: those who will be monitored with this new automated system from June 2022 to January 2024, and those who were monitored using traditional methods before June 2022.
To participate in this study, patients need to be between 18 and 100 years old and have been in the ICU for more than 48 hours. Unfortunately, patients without a urinary catheter (a tube that helps drain urine) or those who stayed in the ICU for less than 48 hours won't be included. The study aims to include around 900 patients in each group, and researchers will carefully analyze the data to see if the automated monitoring system makes a difference in preventing kidney injury and managing fluid levels in patients. If you or a loved one meets the criteria, this study could provide valuable insights into improving care for ICU patients.
Gender
ALL
Eligibility criteria
- • Inclusion Criteria: Patients aged 18-100, who were admitted to the General Intensive Care Unit in Meir Medical Center from January 2021 to January 2024, and had admission times longer than 48 hours.
- • -
- • Exclusion Criteria: Patients without a urinary catheter, Patients with admission times less than 48 hours.
- • -
About Meir Medical Center
Meir Medical Center is a leading healthcare institution dedicated to advancing medical research and improving patient outcomes through innovative clinical trials. As a prominent sponsor of clinical studies, Meir Medical Center is committed to fostering collaboration among healthcare professionals, researchers, and patients to explore new therapies and treatment modalities. With a focus on ethical practices and patient safety, the center aims to contribute significantly to the scientific community while enhancing the quality of care provided to its diverse patient population. Through its robust infrastructure and multidisciplinary approach, Meir Medical Center stands at the forefront of medical innovation, driving progress in various therapeutic areas.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Kfar Saba, , Israel
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials